Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia

References

• Koschmieder S, Halmos B, Levantini E, et al. Dysregulation of the C/EBPα differentiation pathway in human cancer. J Clin Oncol. 2009;27(4):619–628.
   PubMed Web of Science ®Google Scholar
• Quintana-Bustamante O, Smith S L-L, Griessinger E, et al. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. Leukemia. 2012;26(7):1537–1546.
   PubMed Web of Science ®Google Scholar
• Fasan A, Haferlach C, Alpermann T, et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia. 2014;28(4):794–803.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Rajput S, Mandava S, et al. Molecular Evaluation of CEBPA GeneMutation in Normal Karyotype Acute Myeloid Leukemia: A Comparison of Two Methods and Report of Novel CEBPA Mutations from Indian Acute Myeloid Leukemia Patients. Genet Test Mol Biomarkers. 2012;16(7):707–715.
   PubMed Web of Science ®Google Scholar
• Ahn JY, Seo K, Weinberg O, et al. A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. J Mol Diagn. 2009;11(4):319–323.
   PubMed Web of Science ®Google Scholar
• Pabst T, Eyholzer M, Fos J, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343–1346.
   PubMed Web of Science ®Google Scholar
• Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469–2475.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang F, Chen X, et al. Companion gene mutations and their clinical significance in AML with double mutant CEBPA. Cancer Gene Ther 2020;27(7-8):599–606.
   PubMed Web of Science ®Google Scholar
• Su L, Tan Y, Lin H, et al. Mutational spectrum of acute myeloid leukemia patients with doubleCEBPA mutations based on next-generation sequencing and its prognostic significance. Oncotarget. 2018;9(38):24970–24979.
   PubMedGoogle Scholar
• Grossmann V, Haferlach C, Nadarajah N, et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis. Br J Haematol. 2013;161(5):649–658.
   PubMed Web of Science ®Google Scholar
• Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the children's oncology group. Blood. 2010;116(5):702–710.
   PubMed Web of Science ®Google Scholar
• Haider I, Kumar C, Jain G, et al. Hotspots mutational analysis of wilms tumor 1 gene in acute myeloid leukaemia; prevalence and clinical correlation in north Indian population. Am J Blood Res. 2020;10(5):179–189.
   PubMed Web of Science ®Google Scholar
• Krauth MT, Alpermann T, Bacher U, et al. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia. 2015;29(3):660–667.
   PubMed Web of Science ®Google Scholar
• Luo S, Yu K, Yan QX, et al. Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2014;55(2):349–357.
   PubMed Web of Science ®Google Scholar
• Kern W, Bacher U, Haferlach C, et al. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol. 2010;23(3):379–390.
   PubMed Web of Science ®Google Scholar
• Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet. 2001;27(3):263–270.
   PubMed Web of Science ®Google Scholar
• Kumar D, Mehta A, Panigrahi MK, et al. NPM1 mutation analysis in acute myeloid leukemia: comparison of three techniques - sanger sequencing, pyrosequencing, and real-time polymerase chain reaction. Turk J Haematol. 2018;35(1):49–53.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Nishiyama T, Ishiyama K, et al. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol. 2016;103(1):53–62.
   PubMed Web of Science ®Google Scholar
• Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 wilms' tumor locus. Cell. 1990;60(3):509–520.
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Suarez SF, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868–876.
   PubMed Web of Science ®Google Scholar
• Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87(7):2878–2884.
   PubMed Web of Science ®Google Scholar
• Sugiyama H. Wilms’ tumor GeneWT1: Its oncogenic function and clinical application. Int J Hematol. 2001;73(2):177–187.
   PubMed Web of Science ®Google Scholar
• Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer. 2011;11(2):111–121.
   PubMed Web of Science ®Google Scholar
• Lyu X, Xin Y, Mi R, et al. Overexpression of wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PLoS One. 2014;9(3):e92470.
   PubMed Web of Science ®Google Scholar
• Šálek C, Vydra J, Cerovská E, et al. WT1 expression in peripheral blood at diagnosis and during the course of early consolidation treatment correlates With survival in patients With intermediate and poor-risk acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(12):e998–e1009.
   PubMed Web of Science ®Google Scholar
• Ahmad F, D’Souza W, Mandava S, et al. Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute myeloid leukemia: determination of incidence, distribution patterns, and report of a novelKITmutation. Leuk Lymphoma. 2011;52(5):865–876.
   PubMed Web of Science ®Google Scholar
• Luo P, Jing W, Yi K, et al. Wilms’ tumor 1 gene in hematopoietic malignancies: clinical implications and future directions. Leuk Lymphoma. 2020;61(9):2059–2067.
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang B, Liu J, et al. Case report of acute myeloid leukemia with “WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19” developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy. Medicine (Baltimore). 2020;99(3):e18888.
   PubMed Web of Science ®Google Scholar
• Becker H, Marcucci G, Maharry K, et al. Mutations of the wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Blood. 2010;116(5):788–792.
   PubMed Web of Science ®Google Scholar
• Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841–1855.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate Its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015;57(4):662–673.
   PubMed Web of Science ®Google Scholar
• Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222–5231.
   PubMed Web of Science ®Google Scholar
• Virappane P, Gale R, Hills R, et al. Mutation of the wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom medical research council adult leukaemia working party. J Clin Oncol. 2008;26(33):5429–5435.
   PubMed Web of Science ®Google Scholar
• Tien FM, Hou HA, Tang JL, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018;103(11):e510–e513.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang Y, Hu J, et al. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database. Hematology. 2020;25(1):79–84.
   PubMed Web of Science ®Google Scholar